Figure 5

STS protects against lung inflammatory responses and oxidative stress in mouse COPD model. Comparison of levels of IL-6 (A), KC (B), MCP-1 (C) and cell counts (D) in BALF from CTL, CS, CS plus STS (CS + STS) and STS-treated mice. Comparison of GSH/GSSG ratio (E) in mouse lungs from CTL, CS, CS plus STS (CS + STS) and STS-treated mice. *P < 0.05 and **P < 0.01 (n = 8–10 mice per group). (F–G) Cells were treated with CSE (1%, 2%, 5%, 10%, 20%) or STS (5 μg/ml, 10 μg/ml, 20 μg/ml, 40 μg/ml and 60 μg/ml) for 48 hours and cell viability was measured by a CCK8 assay. 16HBE cells were treated with 2% CSE for 48 hours with or without 2 h of STS (10 μg/ml) pretreatment, the expression of IL-6 (H) and IL-8 (I) in cell culture medium was measured. **P < 0.01, n = 5. STS, Sodium tanshinone IIA sulfonate; CS, cigarette smoke; CSE, cigarette smoke extract; KC, keratinocyte chemoattractant; MCP-1, monocyte chemoattractant protein-1.